Caption Management’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-63,500
| Closed | -$2.55M | – | 1634 |
|
|
2026
Q1 | $2.55M | Hold |
63,500
| – | – | 0.01% | 754 |
|
|
2025
Q4 | $1.6M | Sell |
63,500
-4,300
| -6% | -$101K | 0.01% | 908 |
|
|
2025
Q3 | $1.53M | Buy |
+67,800
| New | +$1.58M | 0.01% | 944 |
|
|
2025
Q2 | – | Sell |
-30,000
| Closed | -$656K | – | 1421 |
|
|
2025
Q1 | $656K | Sell |
30,000
-55,500
| -65% | -$1.53M | 0.01% | 1027 |
|
|
2024
Q4 | $2.73M | Buy |
85,500
+25,500
| +43% | +$767K | 0.03% | 586 |
|
|
2024
Q3 | $1.73M | Sell |
60,000
-103,900
| -63% | -$3.85M | 0.03% | 613 |
|
|
2024
Q2 | $6.29M | Buy |
163,900
+103,900
| +173% | +$4.71M | 0.1% | 222 |
|
|
2024
Q1 | $3.53M | Sell |
60,000
-179,300
| -75% | -$11.4M | 0.05% | 382 |
|
|
2023
Q4 | $14.3M | Sell |
239,300
-15,700
| -6% | -$796K | 0.19% | 129 |
|
|
2023
Q3 | $9.7M | Buy |
255,000
+125,000
| +96% | +$5.49M | 0.15% | 165 |
|
|
2023
Q2 | $11.8M | Sell |
130,000
-140,500
| -52% | -$12.1M | 0.21% | 121 |
|
|
2023
Q1 | $17.8M | Buy |
270,500
+200,500
| +286% | +$11.6M | 0.34% | 64 |
|
|
2022
Q4 | $3.62M | Buy |
+70,000
| New | +$3.71M | 0.06% | 398 |
|
|
2022
Q2 | – | Sell |
-648,700
| Closed | -$33M | – | 1420 |
|
|
2022
Q1 | $33M | Buy |
648,700
+428,700
| +195% | +$18.9M | 0.4% | 40 |
|
|
2021
Q4 | $10.4M | Sell |
220,000
-365,300
| -62% | -$14.4M | 0.12% | 222 |
|
|
2021
Q3 | $19.3M | Buy |
585,300
+400,300
| +216% | +$22.5M | 0.22% | 100 |
|
|
2021
Q2 | $11.7M | Buy |
+185,000
| New | +$9.55M | 0.15% | 165 |
|
|
2020
Q4 | – | Sell |
-30,000
| Closed | -$904K | – | 955 |
|
|
2020
Q3 | $904K | Buy |
+30,000
| New | +$896K | 0.02% | 641 |
|
Other funds holding APLS
Caption Management's APLS Position: Q1 2026 in Review
Caption Management sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 254,563 shares — an estimated $5.49M sold.
Caption Management first reported a position in APLS in Q1 2021 and held it in 15 quarters. The position peaked at $23.5M in Q4 2023. 324 funds tracked by Wall St. Rank hold APLS as of Q1 2026.
- Caption Management reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Caption Management sold 254,563 Apellis Pharmaceuticals shares in Q1 2026, an estimated $5.49M.
- Caption Management first reported a position in Apellis Pharmaceuticals in Q1 2021 and held it in 15 quarters.
- Caption Management's Apellis Pharmaceuticals position peaked at $23.5M in Q4 2023.
- 324 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.
Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.